Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Cash (2016 - 2025)

Historic Change in Cash for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $65.4 million.

  • Viking Therapeutics' Change in Cash rose 37725.98% to $65.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $139.1 million, marking a year-over-year increase of 58495.05%. This contributed to the annual value of $139.1 million for FY2025, which is 58495.05% up from last year.
  • Latest data reveals that Viking Therapeutics reported Change in Cash of $65.4 million as of Q4 2025, which was up 37725.98% from $66.5 million recorded in Q3 2025.
  • In the past 5 years, Viking Therapeutics' Change in Cash registered a high of $140.1 million during Q1 2024, and its lowest value of -$151.7 million during Q2 2024.
  • Moreover, its 5-year median value for Change in Cash was $5.2 million (2022), whereas its average is $6.9 million.
  • In the last 5 years, Viking Therapeutics' Change in Cash surged by 119584.6% in 2023 and then crashed by 39645.62% in 2024.
  • Over the past 5 years, Viking Therapeutics' Change in Cash (Quarter) stood at $15.1 million in 2021, then crashed by 53.11% to $7.1 million in 2022, then skyrocketed by 158.1% to $18.3 million in 2023, then tumbled by 229.08% to -$23.6 million in 2024, then soared by 377.26% to $65.4 million in 2025.
  • Its Change in Cash stands at $65.4 million for Q4 2025, versus $66.5 million for Q3 2025 and -$4.0 million for Q2 2025.